Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Card14 Polymorphism and Methotrexate Response in Psoriasis and PsA
NCT06870500Recruiting
- Sponsor
- South Valley University
- Start
- Mar 2025
- Primary completion
- Mar 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Open-label trial of methotrexate in psoriasis and psoriatic arthritis (PsA) (3 arms), sponsored by South Valley University. Primary endpoint: Response of psoriasis and psoriatic arthritis to Methotrexate at 3 months. Started Mar 2025; status: recruiting.
02
Drugs
methotrexate
03
Conditions
psoriasispsoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT06870500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06870500.